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long-acting injectable risperidone. METHODS: Retrospective analysis (Jan 2006-
Dec 2008) of Texas Medicaid data was conducted for patients  18 years old with
schizophrenia (ICD-9: 295.xx). Patients who initiated either oral (oral cohort) or
injectable risperidone (injectable cohort), had no prior risperidone for at least 12
months, and had at least one additional prescription following initiation were
included. Medical care services and costs were compared within and between co-
horts for 12months pre- and post-initiation using paired-, independent t-tests and
McNemar tests. RESULTS: 1544 patients were included (oral cohort: n1261, mean
age  38yrs, 54% male; injectable cohort: n283, mean age39yrs, 61% male). The
injectable cohort (4.6, SD2.9) had a significantly higher mean Chronic Disease
Score (CDS) compared to the oral cohort (3.2, SD2.9) (p0.05). The percent of
patients with at least one psychiatric-related hospitalization significantly de-
creased by 10.6% in the injectable cohort (25.0% to 14.5%; p0.05) compared to 6.1%
in the oral cohort (18.7% to 12.6%; p0.05), and average hospital length of stay (LOS)
was significantly reduced by 2.5 days (4.4 to 1.9 days) versus 0.9 days (2.6 to 1.7
days), respectively (p0.05). Direct mental health-related medical costs signifi-
cantly decreased by $1395 ($4968 to $3573; p0.05) in the injectable cohort com-
pared to $51 in the oral cohort ($1912 to $1861; NS) (p0.05). CONCLUSIONS: For
patients initiated on long-acting injectable risperidone, clinical utilization and eco-
nomic outcomes improved one year post-initiation, as the number hospitaliza-
tions, LOS, and total mental health-related medical costs decreased. While inject-
able cohort patients may be a sicker population (as evidenced by higher CDS and
higher levels of baseline and follow-uputilization and costs), their level of improve-
ment was higher than that of the oral cohort.
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OBJECTIVES: Previous evidence has demonstrated that the presence of psychiatric
comorbidities in patients with ADHD is associated with increased total healthcare
costs. This study examined factors associated with healthcare costs in a commer-
cially-insured population with ADHD and 1 psychiatric comorbidity.METHODS:
Using the Market Scan database (2005–2007), we examined claims for 4,613 com-
mercially-insured patients ages 6 to 17 years with a diagnosis of ADHD (ICD-9:
314.xx) and 1 of the following psychiatric comorbidities: oppositional defiant
disorder, conduct disorder, learning disability, anxiety disorder, and depression.
Percent of days covered (PDC) by 1 ADHD medication was calculated for the
12-month period following index date. The population was divided into two
groups: consistent users (PDC70%) or inconsistent users (PDC70%). Chi-square
tests for categorical variables and t-test or ANOVA for continuous variables were
employed to identify differences between the groups (significant when P0.05).
Generalized linearmodels with gamma-distributed error and log-link were used to
evaluate the association between total healthcare costs and covariates that in-
cluded patient demographics, each comorbidity, and treatment-consistency.
RESULTS: The study population was predominantly male (64.8%), had a mean age
of 12.6 years, and was predominantly urban (87.3%). In specifying the regression
model, the following covariates were significantly associated with the cost out-
come: treatment-consistency, age, gender, insurance type, index year, and each of
the tested psychiatric comorbidities. Relative to consistent users, inconsistent us-
ers had lowermodeled total healthcare costs (P0.0001). Female sex, increased age,
and each of the psychiatric comorbidities were associated with increased total
healthcare cost relative to their counterpartswithout those attributes (P0.0087 for
female sex; P0.0001 for all other covariates). CONCLUSIONS: In the studied pop-
ulation of children and adolescents with ADHD and concurrent mental health
diagnoses, after controlling for significant covariates, inconsistent use of ADHD
medications was associated with lower total healthcare costs than consistent use.
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OBJECTIVES:To evaluate the cost-effectiveness of GXR vs. ATX for the treatment of
ADHD in children and adolescents from a US third-party payer perspective.
METHODS:Aneconomicmodelwas developed to estimate the cost effectiveness of
GXR vs. ATX during a 4-week drug titration period and a 48-week maintenance
period (one-year time horizon). Effectiveness was measured by the number of re-
sponders (defined as patients with 25% reduction in ADHD-Rating Scale-IV total
observed score compared to baseline), and estimated quality-adjusted life years
(QALYs). The model assumed all patients received treatment until the end of titra-
tion and only responders continued treatment afterwards. A uniform constant
discontinuation rate, based on the long-term trials of GXR and ATX, was applied.
Response rates were obtained from a matching-adjusted indirect comparison of
efficacy between GXR and ATX based on the Phase III trials. Published utilities
corresponding to response and non-response health states were applied. Disutility
due to adverse events was applied to the entire titration period. Costs included
published drug wholesale acquisition costs (WAC) in 2010 US dollars. Incremental
cost per QALY and incremental cost per responder were estimated for GXR com-
pared to ATX. Various one-way sensitivity analyses (SA) were conducted to exam-
ine the robustness of the model. RESULTS: Despite the lower WAC unit price, GXR
had an incremental cost of $171 over ATX because more GXR patients achieved
response and continued treatment. In the base case, the cost/QALY was $24,688
and the incremental cost per responder was $1,979. Most scenarios in the one-way
SA resulted in a cost/QALY below $50,000, with the exceptions of increasing GXR or
decreasing ATX costs by 25%. CONCLUSIONS: Compared to ATX, GXR is cost-effec-
tive, at the cost that is lower than the socially acceptable willingness-to-pay
threshold of $50,000/QALY, for the treatment of ADHD in children and adolescents.
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OBJECTIVES: A cost-consequence analysis was performed to assess the economic
implications of changes in cardiometabolic parameters after six-week treatment
with lurasidone vs. other selected atypical antipsychotics in patients with
schizophrenia.METHODS:Amodel using discrete event simulationwas developed
to assess the economic impact from a US payer perspective over a two-year time-
frame. It uses baseline patient-level profiles from lurasidone trials to simulate
changes in cardiometabolic parameters (e.g., LDL, HDL, triglycerides, total choles-
terol, fasting glucose (FG), and BMI) associated with each treatment over six-weeks
using data from lurasidone clinical trials for lurasidone and olanzapine and from
the literature for risperidone, quetiapine IR and XR. Based on the simulations, the
model projects the number of cases requiring pharmacological treatment for hy-
perlipidemia (i.e., LDL130 mg/dL), hyperglycemia (i.e., FG 100-126 mg/DL), as well
as diabetes and cardiovascular events (CVD) using risk equations from the
Framingham Heart Study. Costs (in 2010 values) are accrued according to each
patient’s specific experience with treatments and events over the course of the
simulation. RESULTS: Per 1,000 treated patients, lurasidone is predicted to result in
47, 14, 16, and 2 fewer incident diabetes; 74, 56, 56, and 49 fewer hyperlipidemia
cases; and 191, 82, 82, and 16 fewer hyperglycemia cases than olanzapine, risperi-
done, quetiapine IR, and quetiapine XR, respectively. CVD events are also fewer
with lurasidone, but the differences among treatments areminimal. These clinical
benefits would result in net savings of $857, $414, $431, and $147 per patient,
respectively, and $5,803, $8,657, $9,753, and $7,647 per patient, respectively, if in-
cluding the costs of antipsychotic treatment. CONCLUSIONS: Based on the results
of these economic analyses, lurasidone represents a potentially cost-saving alter-
native for the treatment of patients with schizophrenia.
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OBJECTIVES: To assess cost effectiveness (CE) of antidepressant (AD) therapy, an-
tidepressantswere grouped as tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), and new antidepressants (NADs; SNRIs and others) and
a CEmodel, reflecting relationship between adherence and relapse among patients
with depression in Korea, was developed. METHODS: Effectiveness and cost pa-
rameters were estimated using the KoreanHealth Insurance Review&Assessment
Service (HIRA) claim database (2006-2008). Subjects were selected by age of 18-84,
without a prior history ofmedical visit due to depressionwithin 6-month pre-index
period and with at least 3 psychiatric visits within 3-month post-index period. A
decision-tree model comparing the three ADs groups captured rate of patient ad-
herence, rate and frequency of relapse with/without requiring hospitalization and
healthcare resource utilization associated costs. Adherence was defined as over
75% of Medication Possession Ratio (MPR) in 3-month pre-index period. Costs were
estimated with healthcare system perspective excluding unobservable out-of-
pocket payment (in 2010 KRW). Primary outcome was proportion of patients with
relapse by adherence or nonadherence. RESULTS: The adherence rate was 16.17%
in TCAs, 32.57% in SSRIs, and 34.18% in NADs. The proportions of patients experi-
encing a relapse requiring hospitalization 3.48%, 1.79%, 2.93%, for TCAs, SSRIs,
NADs while the proportion of patients with a relapse not requiring hospitalization
were 33.26%, 13.23%%, 12.59%, respectively. The expected cost of TCAs was
341,187KRW, SSRIs 415,282KRW, NADs 452,586KRW, and expected probabilities to
prevent relapse was 69.9% in TCAs, 76.6% in SSRIs, 74.8% in NADs. The result of
cost-effectiveness analysis was SSRIs is the most cost-effectiveness AD group
(ICER: 1,102,548KRW per relapse prevented). These findings were supported by
sensitivity analysisCONCLUSIONS: The use of SSRIs for treatmentwith depression
in Korean healthcare setting is predicted in this model to results in better clinical
outcomes and lower total healthcare costs over than its comparators.
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OBJECTIVES:Major depressive disorder (MDD) is estimated to affect 3.4% of the US
population. The goal of MDD treatment is remission. We determined the cost-
effectiveness (CE) of adjunct quetiapine fumarate extended-release (QTP XR) ver-
sus adjunct aripiprazole ([ARP] 15 mg/d), and budget impact of adjunct QTP XR in
MDD patients with an inadequate response to previous antidepressant therapy.
METHODS: The CE model used a Markov process to model outcomes in 2nd- and
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